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Primary graft dysfunction (PGD) is a major cause of
early mortality after lung transplant. We aimed to
define objective estimates of PGD risk based on readily
available clinical variables, using a prospective study of
11 centers in the Lung Transplant Outcomes Group
(LTOG). Derivation included 1255 subjects from2002 to
2010; with separate validation in 382 subjects accrued
from 2011 to 2012. We used logistic regression to
identify predictors of grade 3 PGD at 48/72h, and
decision curve methods to assess impact on clinical
decisions. 211/1255 subjects in the derivation and 56/
382 subjects in the validation developed PGD. We
developed three prediction models, where low-risk
recipients had a normal BMI (18.5–25 kg/m2), chronic
obstructive pulmonary disease/cystic fibrosis, and
absent or mild pulmonary hypertension (mPAP<40
mmHg). All others were considered higher-risk. Low-
risk recipients had a predicted PGD risk of 4–7%, and
high-risk a predicted PGD risk of 15–18%. Adding a
donor-smoking lung to a higher-risk recipient signifi-
cantly increased PGD risk, although risk did not change
in low-risk recipients. Validation demonstrated that
probability estimates were generally accurate and that
models worked best at baseline PGD incidences
between 5% and 25%. We conclude that valid esti-
mates of PGD risk can be produced using readily
available clinical variables.
Abbreviations: CF, cystic fibrosis; COPD, chronic
obstructive pulmonary disease; DCD, donation after
cardiac death; ECMO, extra-corporeal membrane oxy-
genation; ILD, interstitial lung disease; LTOG, Lung
Transplant Outcomes Group; PAH, pulmonary arterial
hypertension; PGD, primary graft dysfunction; PH,
pulmonary hypertension; UNOS, United Network of
Organ Sharing
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Introduction
Primary graft dysfunction (PGD) is a form of acute lung
injury affecting the lung allograft within 72 h of transplanta-
tion (1). PGD is common, occurring in 10–30%of transplant
recipients, and it is the leading cause ofmortality in the early
posttransplant period, accounting for nearly 50% of deaths
within the first 30 days (2,3). Additionally, PGD is a risk
factor for other long-term complications of lung transplan-
tation, including bronchiolitis obliterans syndrome (4,5).
Given the clear association between PGD and poor
outcomes after lung transplantation, the ability to risk
stratify recipients prior to transplantation is important for
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several reasons. First, better identification of higher- and
low-risk recipient groups may allow the caring team to be
better prepared for the likelihood of development of PGD.
Second, improved preoperative prediction may facilitate
attempts to safely expand the donor pool by characterizing
lower risk recipient groups. Third, identification of higher-
risk groups of recipients will facilitate therapeutic inter-
ventions or clinical trials aimed at reducing PGD both before
and/or immediately after transplantation.
In this study, we aimed to define and validate objective
estimates of the risk of development of PGD based on
readily available clinical variables. Furthermore, we used
decision curve analysis to demonstrate the net benefit of
different models across a range of baseline PGD incidence.
Methods
Study participants
Subjects aged 18–80 years were enrolled from 11 US transplant centers
within the Lung Transplant Outcomes Group (LTOG), a multicenter
prospective cohort study of lung transplant recipients (bilateral and single)
designed to evaluate risk factors and build a prediction model for PGD (3,6–
11). The derivation population included subjects enrolled betweenMay 2002
and December 2010; we have previously published on individual risk factors
for PGD in the derivation cohort (clinicaltrials.gov identifier: NCT00552357)
(3,10,12). A new and separate validation population included subjects
enrolled between January 2011 and August 2012. Clinical data were
collected prospectively for all subjects (13). The Institutional Review Boards
at each site approved our study. Informed consent was obtained from each
subject.
Outcome definition
PGD in both the derivation and the validation cohorts was graded according
to ISHLT criteria, defined using PaO2/FiO2 ratio and the presence of diffuse
infiltrates in the lung allograft(s) (14). Two blinded physicians interpreted
chest radiographs independently, with adjudication of conflicts by a third
reviewer (kappa for agreement on subject-level grade 3 PGD classification
¼ 0.95) (14). The primary outcome was grade 3 PGD at 48 or 72 h after
transplantation, which has been validated and has been used as an outcome
in previous studies, including clinical trials (3,15,16).
Prediction model development
Variable definitions: Wetransformedcontinuousvariables intocategorical
variables for simplification. As much as possible, categories were based on
clinically useful algorithms (e.g. WHO classification criteria) and not derived
from the data. Body mass index and pulmonary artery pressure were
categorized using WHO classification (17). Two variables representing donor
smokingwere evaluated for use in the predictionmodel. The first variablewas
prospectively collected by LTOG personnel, based on Donor Net data and
reported history by surrogates, and was categorized as yes, any history of
donor smoking, or no, a never smoker (3). The second variable was obtained
from UNOS data, which stratified patients as a ‘‘yes/no/unknown’’ history of
smoking based on a >20 pack-year smoking history. The UNOS dataset
containsadditional cigarette smokingvariables that had toomuchmissingdata
to be included as predictors, including a field for ‘‘continued cigarette use,’’
whichwasmissing in85%ofsubjects. Pulmonary arterypressures at the time
of listing were used preferentially to allow the model to be valid when used
prior to transplant; however, if unavailable, pressures at the time of transplant
were used. Pretransplant recipient diagnosis was grouped into three
categories based on predicted PGD risk: chronic obstructive pulmonary
disease (COPD) or cystic fibrosis (CF), interstitial lung disease (ILD), and all
other diagnoses (including sarcoidosis and PAH) (3).
Missing data in the derivation cohort: To avoid incorrect choices in
candidate predictors and model mis-specification, we engaged in a formal
three-step missing data imputation process in the derivation dataset before
modeling. First, we examined each candidate predictor for out of range
values or errors and set those values to missing. Second, using the method
of chained equations, we created 20 imputed datasets with values for 63
variables using multinomial, ordinal, and linear regressionmodels containing
demographic and clinical factors from both donor and recipients (18–20).
Third, after the imputation process, we identified out-of-range values and
truncated them to fall within clinical bounds.
Statistical analysis in the derivation cohort: For this study, we
considered all possible recipient and donor risk factors as potential
predictors, not just those studied in prior publications (21). We used several
methods to narrow the number of candidate predictors for a final model
based on the development dataset. First, we performed all regressions with
the set of 20 imputed datasets; then estimated statistical significance based
on the sum of between- and within-imputation components of variance to
avoid overstating statistical significance. Second, while we initially consid-
ered the statistical significance of a factor’s association with PGD, we
guarded against overfitting in multivariable models by means of an
automated test of stepwise model-building with bootstrap resampling.
Within each of 1000 bootstrap samples, we performed logistic regression
and noted the number of times that a candidate predictor remained in the
resulting model. To reduce the number of candidate recipient predictors, we
included in the final model only those predictors that were associated with
PGD in the stepwise regressions with p-values<0.05 in>67% of bootstrap
resamples. Although different thresholds may be used to identify candidate
predictors, we felt 67% was most inclusive (22) and conducted sensitivity
analyses of this threshold to include ranges from 25% to 75% of bootstrap
resamples.
After identifying candidate predictors, we focused on the ability of
competing models using only these predictor variables to generate high-
and low-risk patient subgroups with objective estimates of PGD risk. We
chose this method to maximize the clinical utility of the prediction estimates
for groups of patients, as opposed to methods that focus solely on
maximizing discrimination as measured by the area under a ROC curve (or
c-statistic), which may be more suitable to ranking individual patients (such
as on a waitlist) but often do not generate values that have clinical meaning.
To that end, and in addition to calculating c-statistics as measure of model
discrimination, we identified candidate risk thresholds for use in clinical
practice (23) based on a range of baseline PGD incidences, and generated
three different models with varying definitions of low- and high-risk
recipients. Standardized risks for PGD were generated in the derivation
cohort for the high- and low-risk groups. These risk estimates were
generated using postestimation marginalized standardized predictive
probabilities from the regression equations, and represent predicted PGD
risk assuming all subjects have equal distribution of other clinical covariates,
with the only difference being theirmembership in the low- or high-risk group
(24). We identified three potential models: first, a ‘‘restrictive’’ model in
which the presence of any predictor categorized a subject as higher-risk;
second, an ‘‘additive’’ model, in which the presence of two or more
predictors categorized a subject as higher-risk; and third, a ‘‘simple’’ model,
which required having only one predictor necessary to be higher-risk, with
different variable cutoffs. Both the selection of candidate predictors and the
definition of these alternative risk classifications reflected our findings based
on the analysis of candidate predictors and their statistical significance.
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As donor smoking was the only donor variable identified for inclusion as a
potential predictor, we quantified the effect of adding a donor with smoke
exposure on the predicted PGD risk over-and-above the estimated risk based
on recipient variables alone. We accounted for center as a main effect in our
analysis using logistic regression conditioned on center based on previous
data that there was a variable incidence of PGD between centers (3). We did
not perform a stratified analysis within-center because of limited numbers.
In sensitivity analyses, the derivation analysis was also performed within
transplant type, acknowledging inherent differences in single and bilateral
transplant recipients.
In secondary analyses, we used the same set of candidate models to
evaluate prediction of 30-day and 1-year mortality.
Model validation
Study population: The validation set purposely contained data from the
same centers, but from a separate time period immediately following the
development dataset. This approach permitted use of all available data at the
time of model development and then all patients whose data accrued
subsequently for the validation. Temporal validation was also chosen
because other multicenter validation datasets with well-phenotyped PGD
data were not available at the time of study conduct.
We did not employ multiple imputation in the validation dataset to be
consistent with clinical practice where complete data on all subjects is
unlikely.
Validation of PGD probability estimates: Using the predictors identi-
fied in themodel development stage,we tested the predicted and observed
probabilities of PGD in the separate validation dataset. We primarily
focused on whether the observed PGD probabilities in the validation set fell
within the confidence intervals of the predicted probabilities that were
generated in the derivation set (25). We also employed decision curve
analyses to compare alternative models against treating all patients as
either ‘‘low risk’’ or ‘‘high risk’’ (26). Decision curves combine traditional
measures of sensitivity and specificity withmore formal assessment of risk
thresholds at which clinicians and their patients might makes decisions
about risk and treatment choices. They describe (i) whether the candidate
prognostic models will perform better than the alternative of classifying
everyone (or no one) as high PGD risk and (ii) the net benefit of the model
across a range of decision thresholds (where the decision threshold is the
predicted risk of PGD from a particular model). The net benefit is a
calculated number derived by subtracting the proportion of all patients who
are false-positive from the proportion who are true-positive within a range
of threshold probabilities (formula: (true-positive count/n)-(false-positive
count/n)*(pt/1-pt), where pt represents the threshold probability that would
change clinical decision making) (26). Using net benefit at various
probabilities allowed us to generate the decision curve in Figure 1. We
chose this method as a more clinically useful way of assessing the utility of
the prediction model, because it takes into account consequences of
actions across risk thresholds (25). Decision curves plotting the net benefit
on the y-axis versus the threshold PGD probabilities on the x axis, using the
‘‘dca’’ command in STATA v13.
Sample size: Weestimated the number of subjects needed to validate the
model, while maximizing the number of subjects in the derivation cohort to
optimize power for model generation. Since the primary focus was to
identify a group of low-risk patients, we focused on identifying patients
whose predicted probability of PGD was 50% of our estimated baseline
incidence of PGD. We considered this relative reduction in risk of PGD as
clinically significant, which would be commonly accepted as a low-risk
phenotype. As our observed incidence was 17% in prior studies (3), we
estimated that a validation sample of 350with an overall risk of PGD of 8% (a
50% reduction from 17%)would have a risk upper bound of 11% (therefore,
be distinct from the overall incidence of 17%).
STATA v11.2-13.0 (STATA Corp. College Station, TX) was used for all
analyses.
Results
Of the 1255 subjects in the derivation cohort, 211 (17%,
95%CI: 15%, 19%) developed PGD. Of the 382 subjects in
the validation cohort, 56 (15%, 95% CI: 11%, 19%)
developed PGD. In both cohorts, recipients with PGD
were more frequently overweight or obese, had ILD as a
pretransplant diagnosis, and more frequently had moder-
ate-severe pulmonary hypertension (PH) (Table 1). Percen-
tages of data imputed for variables in the derivation cohort
are listed in Table S1.
Derivation
Table 2 presents the results of bootstrap modeling on
variable selection of candidate predictors. Consideration of
alternate thresholds ranging from 25% to 75% did not alter
the predictor variables selected. Recipient factors with
significant predictive utility included a pretransplant diagno-
sis that was not COPD or CF, abnormal body mass index
(BMI), and elevated mean pulmonary artery pressure
(mPAP, which was defined as >25mmHg). Using these
three recipient predictors, we were able to categorize
recipients into ‘‘higher risk’’ and ‘‘low risk.’’ We tested the
three recipient prediction models based on different cutoffs
using diagnosis, BMI, and PA pressure, summarized in
Table 3. Table 4 displays PGD probability estimates for the
three models generated. The first model, or the ‘‘restrictive
model,’’ identified 14% of recipients as low risk, which was
defined as no PGD predictors, i.e. normal BMI, no
pulmonary hypertension, and a diagnosis of COPD or CF.
Low-risk recipients in thismodel had a predicted risk of PGD
of 5% (95% CI: 0, 10). In the high-risk category (86% of
recipients), therewas a predicted PGD risk of 15% (95%CI:
13, 18%). The second, or ‘‘additive model,’’ categorized
significantlymore recipients as low risk (37%). In thismodel,
a low-risk recipient had at least one of the predictors, and
had a predictedPGD risk of 7%, (95%CI: 4, 11%) and a high-
risk recipient (63%) had a predicted PGD risk of 18% (14,
21%). Finally, the third model, the ‘‘simple model,’’
identified 24% as low risk. This model also categorized a
low-risk recipient as having no more than one predictor, but
considered high-risk recipients to have a mPAP>40mmHg
(as opposed to 25mmHg in the restrictive model). In this
model, a low-risk recipient had a predicted incidence of PGD
of 6% (95% CI: 2, 10%), and the low-risk phenotype was
defined by a pretransplant diagnosis of COPD or CF, normal
BMI (18.5–25), and either absent or mild pulmonary
hypertension (mPAP<40mmHg). The higher-risk recipient
had a predicted PGD risk of 16% (95% CI: 13, 19%). In all
models, the goodness-of-fit test indicated good calibration
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(p> 0.05 for all three). C-statisticswere similar in themodels
(Table 4).
History of any smoking was the only donor risk factor that
consistently predicted PGD. We therefore evaluated the
impact of adding a lung from a smoking donor to
recipients in the higher- and low-risk categories (Table 4).
The addition of a donor with smoke exposure to a higher-
risk recipient significantly increased the risk of PGD in all
three models. However, the addition of a donor with
smoke exposure to a low-risk recipient did not significant-
ly increase the risk of PGD in the derivation set. Similar
results were found when we evaluated the model
stratified by single or bilateral transplant procedure type
(Table S3).
Validation cohort
We next evaluated whether observed PGD incidences in
the validation cohort were similar to those predicted from
the derivation cohort (Table 4). The observed incidences of
PGD in the low-risk groups ranged from 5% to 11% and fell
within confidence intervals of predicted probabilities in all
strata of all models. In the higher-risk groups, again the
observed incidences of PGD were 13–16% and fell within
predicted risk values from the derivation cohort for these
strata. With the addition of donor with smoke exposure to
the low-risk groups, the observed risk increased to 13–
15%; however, the small number of subjects in these strata
limited our ability to determine the significance of the
increase in risk. In particular, there were low numbers of
subjects with moderate or severe pulmonary hypertension
in the validation cohort. In the higher-risk groups, the
addition of donor lungs from smokers significantly
increased the PGD risk in all three models, and observed
incidences in the validation cohort all fell within the
predicted risks from the derivation cohort for these strata.
Next, we classified patients according to the three risk
models and assessed whether use of these risk models
would increase overall net benefit across a range of
thresholds of PGD incidences, compared to the alternatives
of defining all patients (or no patients) as high risk. As
displayed in Figure 1, for expected ranges of incidences of
5–25%, use of the three prediction models demonstrated
benefit over a strategy of treating everyone as either higher
or low risk. As shown in Figure 1, the ‘‘restrictive model’’
seemed to perform better at lower PGD thresholds (as low
as 5%), while the ‘‘additive model’’ performed best at
higher PGD risk thresholds.
Mortality prediction
Given previously demonstrated association of PGD with
early mortality, we tested the utility of our model for
mortality prediction. Mortality information was available
on 1229 of the 1255 subjects (98%). In the derivation
cohort, 98 subjects died within 90 days of transplant (8%),
and 167 died within 1 year of transplant (13%). Numbers
were too small to evaluate the association with mortality
Figure 1: Decision curve analysis of alterna-
tive strategies for prognostic models for
primary graft dysfunction after lung trans-
plantation. The plot compares three models
against the alternatives of (a) considering every-
one to be higher-risk (downward sloping dotted
gray line) or (b) foregoing any prognosticmodeling
and treating no one as being at high risk (solid
horizontal line). The y axis is net benefit (the
tradeoff between true-positive and false-positive
classifications for high-risk status), and the x axis
represents the threshold probability for classify-
ing a patient as being at high risk for PGD. Net
benefit will vary depending on the threshold risk
because that threshold probability reflects the
relative loss of missing high-risk patients (false
negatives) and of considering too many low-risk
patients (false positives). Because the threshold
might vary with individual patients and their
centers, the decision curves plot net benefit
against a range of thresholds. In this setting,
typical threshold probabilities might range from
5% to 20%. In that range of thresholds, the
proposed prognostic models are not only simple
to implement but also superior in net benefit in
the classification of higher-risk PGD patients than
treating all patients as being at high risk.
Prediction of PGD
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in the validation cohort (only 21 of 376 with mortality
information died within 90 days). When using any of the
three models in the derivation cohort, low-risk recipients
had a lower risk of 90-day mortality than higher-risk
recipients. When we evaluated 1-year mortality, low-risk
recipients again had a lower mortality than higher-risk
recipients. The addition of a smoking donor did not
significantly affect the predicted risk of 90-day or 1-year
mortality (Table 5).
Discussion
In this study, we generated three prediction models for
PGD that distinguish low-risk from high-risk recipients for
PGD groups based on variables that are readily available
prior to transplantation. In a subsequent validation sample,
we validated these PGD estimates in recipient groups and
then used decision curve analysis to compare alternative
models across realistic risk thresholds. We found that
abnormal body weight, moderate-severe PH, or a pretrans-
plant diagnosis other thanCOPDor CF determined a higher-
Table 1: Univariate analysis of donor, recipient in peri-operative variables stratified by primary graft dysfunction (PGD) status
Derivation Validation
Covariates PGD (n¼211) Non-PGD (n¼1044) PGD (n¼56) Non-PGD (n¼326)
Donor variables
Male gender, n (%) 115 (55) 646 (62) 33 (59) 217 (67)
Age, mean 35.2 34.4 37.1 34.9
Race, n (%)
Caucasian 135 (65) 660 (64) 35 (65) 180 (55)
African American 43 (21) 214 (21) 12 (22) 83 (26)
Other 29 (14) 160 (15) 7 (13) 62 (19)
Any smoking, yes 92 (48) 335 (35) 22 (39) 64 (20)
Recipient variables
Male gender 117 (55) 592 (57) 30 (54) 192 (59)
Age, mean 53.3 53.6 54.2 56.7
BMI category, n (%)
<18.5 11 (9) 77 (12) 3 (5) 29 (9)
18.5–25 30 (25) 281 (43) 23 (41) 126 (39)
25–30 51 (41) 224 (34) 18 (32) 126 (39)
>30 31 (25) 79 (12) 12 (21) 45 (14)
Pulmonary diagnosis, n (%)
COPD 56 (27) 418 (40) 14 (25) 124 (38)
Idiopathic pulmonary fibrosis 91 (43) 364 (35) 30 (54) 133 (41)
Cystic fibrosis 16 (8) 162 (16) 5 (9) 41 (13)
Sarcoidosis 17 (8) 26 (2) 1 (2) 7 (2)
PAH 12 (6) 28 (3) 5 (9) 9 (3)
Other 19 (9) 45 (4) 1 (2) 12 (4)
mPAP severity category, n (%)
<25mmHg (normal) 71 (41) 463 (51) 23 (41) 176 (54)
25–40mmHg (mild) 70 (40) 380 (42) 27 (48) 122 (37)
41–55mmHg (moderate) 22 (13) 41 (5) 5 (9) 22 (7)
>55mmHg (severe) 11 (6) 20 (2) 1 (2) 6 (2)
Race, n (%)
Caucasian 167 (79) 902 (86) 45 (80) 292 (90)
African American 32 (15) 84 (8) 6 (11) 22 (7)
Other 12 (6) 57 (5) 5 (9) 12 (4)
BMI, body mass index; mPAP, mean pulmonary artery pressure; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung
disease; PGD, primary graft dysfunction. Percentages may not exactly equal 100% because of rounding.
PGD is defined as grade 3 PGDon day 2 or 3 after lung transplantation. The distribution of variables presented is from the pre-imputation data
in the derivation cohort. The validation data reflects the data used in the analysis
Table 2: Results of logistic regressionmodel to evaluate candidate
predictors in the recipient in each bootstrap sample of the
derivation set (n¼1000)
Candidate predictor variable
% of 1000 datasets
predictor p<0.05
Transplant type 4.70
BMI category 99.40
Recipient diagnosis 99.60
Recipient gender and parity 5.70
Mean PA pressure 99.80
Donor smoking (any) 77.4
>20-pk-year history of donor smoking 13.0
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risk recipient. Furthermore, we identified history of
smoking in a donor as significantly increasing the risk of
PGD in higher-risk recipients. Finally, we demonstrated that
our prediction models are also useful in predicting mortality
based on recipient factors. Predicted probabilities from the
model were validated in a separate, temporally distinct,
population.
We believe our models are useful in several ways. First,
these simple models can be used to identify those
recipients who are at higher risk, so that clinicians can
prepare patients and families for the possibility of PGD and
practitioners can anticipate the need for salvage therapy,
such as ECMO. Second, although the low-risk groups are
relatively small, we believe the information is useful at the
time of transplant, to facilitate the use of emerging
therapies aimed at expanding donors in these lower-risk
recipients. Finally, we presented several models, which
perform similarly, to allow each center to evaluate the
model based on the risk profile of the potential recipients
and their threshold of an acceptable PGD risk.
While there are many ways to approach predictive
modeling, we chose to focus on identifying subgroups of
recipients and generating objective estimates of PGD risk
for these groups. We then validated these risk estimates in
a separate population, as evidenced by the observed
probabilities falling within the confidence intervals of the
predicted probabilities. While the models demonstrated
good fit and generated reproducible PGD probabilities, the
c-statistics were not very high, likely because we chose to
define recipient groups yielding two discrete categories of
Table 3: Definition of each model
Model Low risk High risk
Restrictive Normal BMI (BMI<25) AND
Mean PAP<25 AND COPD or CF
One of the following:
Abnormal BMI (BMI>25)
Mean PAP>25
Any diagnosis other than COPD or CF
Additive Either no risk factors or one of the
following: Abnormal BMI OR
Mean PAP >25 OR Any diagnosis
other than COPD or CF
Two or more:
Abnormal BMI
Mean PAP >25
Any diagnosis other than COPD or CF
Simple Normal BMI (BMI<25) AND
Mean PAP <40 AND
COPD or CF
One of the following:
Overweight or obese
OR Non-COPD or CF OR mPAP >40
COPD, chronic obstructive pulmonary disease; CF, cystic fibrosis; BMI, body mass index.
Table 4: Predicted risk of PGD in derivation and observed risk in the validation cohort for 3 variation of the predictive model
Derivation Validation
Model % of 1255
Predicted risk
of PGD (95% CI) AUC (95% CI) % of 382
Observed incidence
of PGD (%)
Restrictive 0.67 (0.64, 0.71)
Low risk 14 5 (0,10) 11 5 (0,16)
Low risk þ smoking donor 5 4 (0,10) 9 13 (3,27)
High risk 86 15 (13,18) 89 16 (12,20)
High risk þ smoking donor 33 24 (20,28) 20 27 (18,39)
Additive 0.64 (0.60, 0.68)
Low risk 37 7 (4,11) 35 11 (6,18)
Low risk þ smoking donor 14 11 (6,16) 9 15 (5,31)
High risk 63 18 (14,21) 65 16 (12,21)
High risk þ smoking donor 24 28 (22,33) 14 32 (20,46)
Simple 0.63 (0.59, 0.67)
Low risk 25 6 (2,10) 22 6 (2,13)
Low risk þ smoking donor 10 9 (4,15) 5 15 (3,40)
High risk 75 16 (13,19) 78 13 (9,17)
High risk þ smoking donor 28 26 (21,31) 17 29 (19,42)
The numbers in the derivation cohort represent the predicted risk of PGD based on each model. The numbers in the validation cohort
represent the actual risk once themodels were used to evaluate how frequently PGD occurred in each risk group. The observed incidences
in the validation cohort are similar to the predicted incidences from the derivation cohort.
Prediction of PGD
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risk. Other methods, such as those based on maximizing c-
statistics curves may yield outputs that, while potentially
useful for ranking individual patients (such as on a wait list),
do not have direct clinical meaning in estimating PGD risk
for patient groups (26). In contrast, we chose to create PGD
probability estimates for simple subgroups of patients, and
used decision curve analysis to demonstrate the utility of
the predictive models. Our models worked best at PGD
incidences between 5% and 25%. At incidences below or
above this range, our models do not add significant
prognostic utility over treating everyone as high risk. Based
on our prior data, the incidence of PGD is around 15–17%,
therefore, we believe that our model will be applicable at
most transplant centers.
We chose to include all three models so that the
practitioners may choose which model best applies to
their practice, based on various factors such as the
acceptable threshold in their practice that would character-
ize a recipient as lowor high risk and the incidence of PGDat
their center. For example, if the goal at a particular center is
a PGD risk of 5%, the more restrictive model may be best
suited for identifying low-risk recipients, as shown in
Figure 1. At the time of allocation, the risk of PGD can be
readily estimated using ourmodel and allow for the ability to
make appropriate management decisions. For example,
being prepared for the use of ECMO or other salvage
therapies prior to the transplant may facilitate preparation
for early interventions and avoid emergent rescue of a
potentially rapidly deteriorating patient. Likewise, objective
PGD probability estimates may have utility in preparing
recipients for the possibility of posttransplant complica-
tions. In addition, our model risk stratifies recipients to
provide a framework for refinement of use of extended
criteria, DCD, or ex vivo conditioned donor lungs.
Donor smoke exposure conferred a significant predictive
impact for PGD risk in the higher-risk recipient. Prior work
has established that use of lungs from donors with smoke
exposure led to worse outcomes after lung transplant;
however, overall waiting list mortality was increased if
lungs from donors with smoke exposure were not used
(27). However, in U.S. administrative datasets this effect is
not consistent (28), perhaps due to the way smoke
exposure is defined. All three of the models demonstrated
that while addition of a donor with smoke exposure to the
low-risk recipient group increased the risk of PGD; the risk
increase did not reach a level that would likely favor the
alternative of not being transplanted. In contrast, the use of
a donor with smoke exposure in the higher-risk recipient
group conferred an increased PGD risk. However, use of
lungs from donors with a smoke exposure should be
considered acceptable pending more accurate quantifica-
tion of smoke exposure. Yet, care providers may choose to
prepare for a higher risk of PGD when using donors with
smoke exposure in high-risk recipients as defined by our
models. Importantly, the current methods for defining and
quantifying donor smoke exposure seem inadequate, as
they rely on proxy reports of timing, quantity, and duration
of smoke exposure. Recently, the use of biochemical
measures to quantify tobacco exposure more accurately in
critically ill patients has yielded promising results and may
represent a method that may improve prediction in the lung
donor population (29). Likewise, BMImay be an inadequate
measure of adiposity, and may be better quantified by
biochemical or imaging methods (10,30). In the future,
these models may aid in allocation decisions, such as
matching a low-risk recipient with a donor who has smoke
exposure; however, improved measurement of predictor
variables, as well as clarification of the mechanisms by
which they increase PGD risk are necessary steps prior to
changing policy (29).
The current work builds on our prior studies of PGD by
employing advanced statistical methods aimed at selecting
those variables with the greatest predictive utility to define
subgroups of patients with lower and higher risk, and by
using a separate validation population of nearly 400 new
Table 5: Predicted risk of a) 90-day and b) 365-day mortality in
derivation cohort
Model
Predicted risk of 90-day
mortality (95% CI)
a) Restrictive
Low risk 6 (1,10)
Low risk þ smoking donor 2 (0,5)
High risk 8 (6,10)
High risk þ smoking donor 10 (7,13)
Additive
Low risk 6 (3,9)
Low risk þ smoking donor 8 (4,12)
High risk 8 (6,11)
High risk þ smoking donor 10 (6,13)
Simple
Low risk 5 (2,8)
Low risk þ smoking donor 6 (1,10)
High risk 9 (7,11)
High risk þ smoking donor 10 (6,13)
Model
Predicted risk of 1-year
mortality (95% CI)
b) Restrictive
Low risk 8 (3,13)
Low risk þ smoking donor 10 (2,17)
High risk 15 (12,17)
High risk þ smoking donor 14 (11,17)
Additive
Low risk 11 (8,15)
Low risk þ smoking donor 13 (8,18)
High risk 15 (12,18)
High risk þ smoking donor 14 (10,18)
Simple
Low risk 9 (6,13)
Low risk þ smoking donor 9 (4,15)
High risk 15 (12,18)
High risk þ smoking donor 16 (12,20)
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subjects to validate the risk estimates in these groups
(3,10). Many prior studies sought to identify individual
independent risk factors whereas this study employed
different modeling techniques to identify subgroups of
patients with distinct predicted probabilities of PGD based
on combined variables that are readily available and present
prior to the transplant episode. In the validation population,
we found that our model was better than treating everyone
as either high risk or no risk. Furthermore, we evaluated
donor and recipient prediction separately, and then
assessed the impact of donor factors on the recipient-
based model. Prior to our study, validation of PGD
prediction in a multicenter prospectively-assessed popula-
tion had not been attempted.
There are limitations to this study. We used a temporal
validation population, meaning subjects for the validation
were taken from the same centers in an ongoing
prospective cohort study but transplanted at a different
timepoint. However, subjects from this study were
recruited from 11 centers throughout the United States;
therefore, we believe there is adequate diversity in the
validation cohort. Additionally, although temporal validation
could introduce bias, there have been minimal changes in
donor or recipient management for PGD during this time
period. Furthermore, as our study is a large multicenter
study, our temporal validation population represents an
external population with representation of many centers;
alternate multicenter external datasets with well-pheno-
typed PGD are not currently available. Our validation study
was designed and powered to provide probability estimates
in the overall population; therefore, we were unable to
perform stratified analyses in the validation set (e.g. by
transplant type). There was significant variation in the
recruitment of patients by center, with both number and
percent of subjects enrolled between centers varying
which may have contributed to the differences in risk by
center. However, we derived our model conditioned on
center, with the goal of identifying universal factors not
affected by center variations. Our multivariable bootstrap
methods for variable selection included a threshold of 67%,
which may have been considered restrictive, perhaps
excluding individual variables that appear to have univariate
associations with PGD (such as race). However, our
multivariable models methods were focused on identifying
stable and generalizable groups of predictor variables, and
did not yield different results when this threshold was
varied between 25% and 75%. We were limited in our
ability to validate the effects of donor smoke exposure on
low-risk recipients due to low numbers in this stratum and
ensuing wide confidence intervals. In particular, there were
low numbers of subjects with moderate or severe
pulmonary hypertension in the validation population. We
included both single and bilateral lung transplant recipients
in our analysis. PGD grading in single lung transplants can
potentially be biased given intrinsic v/qmismatch and shunt
after transplant; however, we have published multiple prior
studies using both single and bilateral transplants, and have
also presented a sensitivity analysis stratified by transplant
type, which did not significantly change results.
In conclusion, we have developed and validated simple
prediction models that easily categorize recipients into
higher- and low-risk groups with reproducible estimated
probabilities of PGD. Logical future directions include
impact studies of these models in clinical practice, studies
focused on improving measurement of specific predictors
such as smoke exposure and obesity, and targeted
intervention studies based on risk estimates generated
for lower- and higher-risk subgroups.
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